Managing poor ovarian reserve, defined by Anti-Müllerian Hormone (AMH) levels under 1.0 ng/ml, represents an intricate challenge in assisted reproduction. Historically, these patients directly transitioned to donor egg protocols. However, modern regenerative biotechnology introduces Ovarian Platelet-Rich Plasma (PRP) intra-follicular therapy. According to Prof. (Dr.) Abha Majumdar, understanding the true scientific scope of this autologous growth-factor procedure helps low-reserve patients establish clear, realistic expectations.
Ovarian PRP utilizes the patient’s own blood plasma, processed via high-speed centrifugation to isolate concentrated platelets. These platelets contain heavy reserves of vital growth agents, including Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor (TGF). Consequently, infusing this biological cocktail into the ovarian stroma triggers a localized healing response.
Furthermore, the therapy aims to awaken dormant primordial follicles residing inside the ovarian tissue layers. While it cannot generate brand-new eggs, it optimizes the vascular blood supply to existing follicles. Therefore, this enhanced cellular environment can improve the quantity and structural quality of oocytes recovered during subsequent stimulation cycles.
Professor’s Medical Insight: Ovarian PRP is not a magic cure-all that reverses ovarian aging overnight. It serves as a highly targeted option for specific women with low AMH or Premature Ovarian Insufficiency (POI) who are strongly determined to attempt conception using their own genetic material before considering donor options.
The entire autologous therapeutic process operates as a safe, highly controlled outpatient procedure under standard sedation:
| Procedure Steps | Clinical Action Breakdown | Expected Clinical Metric |
|---|---|---|
| Blood Processing | Doctors draw approximately 15-20 ml of autologous peripheral blood and process it inside a sterile double-spin centrifuge. | Isolates highly concentrated platelet layers cleanly. |
| Targeted Injection | Using a specialized transvaginal ultrasound needle under brief sedation, the clinician injects the activated plasma directly into both ovaries. | Delivers healing growth factors to the ovarian stroma. |
| Monitoring Phase | The patient’s baseline AMH and Antral Follicle Count (AFC) metrics are closely tracked over the subsequent 4 to 12 weeks. | Identifies any upward shifts in active follicular growth. |
Clinical data shows varying response patterns across populations. Specifically, younger women experiencing unexplained premature ovarian insufficiency demonstrate more promising outcomes than advanced maternal age groups. Our medical team filters candidates strictly based on their physiological health baselines to maintain exceptional clinical safety and transparency.
Ultimately, navigating low ovarian reserve requires combining state-of-the-art regenerative treatments with completely honest counseling. By understanding the genuine science behind ovarian priming protocols, couples can make well-informed, safe decisions throughout their reproductive journey.
Medically Reviewed & Approved By: Prof. (Dr.) Abha Majumdar, Director & Head of the Centre of IVF, Sir Ganga Ram Hospital, New Delhi. A Distinguished International Leader in Regenerative Reproductive Medicine, Follicular Dynamics, and Customized Low-AMH Protocols.
